2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers
OBJECTIVES/SPECIFIC AIMS: Objectives and goals of this study will be to: (1) compare fecal microbiota and fecal organic acids in irritable bowel syndrome (IBS) patients and controls and (2) investigate the association between colonic transit and fecal microbiota in IBS patients and controls. METHODS...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2018-06-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866118000754/type/journal_article |
| _version_ | 1811156733436887040 |
|---|---|
| author | Andrea Shin David Nelson John Wo Michael Camilleri Toyia James-Stevenson Robert Siwiec Matthew Bohm Anita Gupta |
| author_facet | Andrea Shin David Nelson John Wo Michael Camilleri Toyia James-Stevenson Robert Siwiec Matthew Bohm Anita Gupta |
| author_sort | Andrea Shin |
| collection | DOAJ |
| description | OBJECTIVES/SPECIFIC AIMS: Objectives and goals of this study will be to: (1) compare fecal microbiota and fecal organic acids in irritable bowel syndrome (IBS) patients and controls and (2) investigate the association between colonic transit and fecal microbiota in IBS patients and controls. METHODS/STUDY POPULATION: We propose an investigation of fecal organic acids, colonic transit and fecal microbiota in 36 IBS patients and 18 healthy controls. The target population will be adults ages 18–65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Exclusion criteria are: (a) history of microscopic colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, liver disease, or elevated AST/ALT>2.0× the upper limit of normal, (b) prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy >6 months before study initiation, (c) ingestion of prescription, over the counter, or herbal medications affecting gastrointestinal transit or study interpretation within 6 months of study initiation for controls or within 2 days before study initiation for IBS patients, (d) pregnant females, (e) antibiotic usage within 3 months before study participation, (f) prebiotic or probiotic usage within the 2 weeks before study initiation, (g) tobacco users. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis and frozen. Frozen aliquots will be shipped to the Metabolite Profiling Facility at Purdue University and the Mayo Clinic Department of Laboratory Medicine and Pathology for SCFA and bile acid measurements, respectively. Analysis of fecal microbiota will be performed in the research laboratory of Dr David Nelson in collaboration with bioinformatics expertise affiliated with the Nelson lab. Colonic transit time will be measured with the previously validated method using radio-opaque markers. Generalized linear models will be used as the analysis framework for comparing study endpoints among groups. RESULTS/ANTICIPATED RESULTS: This study seeks to examine the innovative concept that specific microbial signatures are associated with increased fecal excretion of organic acids to provide unique insights on a potential mechanistic link between altered intraluminal organic acids and fecal microbiota. DISCUSSION/SIGNIFICANCE OF IMPACT: Results may lead to development of targets for novel therapies and diagnostic biomarkers for IBS, emphasizing the role of the fecal metabolome. |
| first_indexed | 2024-04-10T04:56:16Z |
| format | Article |
| id | doaj.art-b23191136333416080efe019a0bb7c62 |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-10T04:56:16Z |
| publishDate | 2018-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-b23191136333416080efe019a0bb7c622023-03-09T12:30:16ZengCambridge University PressJournal of Clinical and Translational Science2059-86612018-06-012121310.1017/cts.2018.752103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteersAndrea Shin0David Nelson1John Wo2Michael Camilleri3Toyia James-Stevenson4Robert Siwiec5Matthew Bohm6Anita Gupta7Indiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineOBJECTIVES/SPECIFIC AIMS: Objectives and goals of this study will be to: (1) compare fecal microbiota and fecal organic acids in irritable bowel syndrome (IBS) patients and controls and (2) investigate the association between colonic transit and fecal microbiota in IBS patients and controls. METHODS/STUDY POPULATION: We propose an investigation of fecal organic acids, colonic transit and fecal microbiota in 36 IBS patients and 18 healthy controls. The target population will be adults ages 18–65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Exclusion criteria are: (a) history of microscopic colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, liver disease, or elevated AST/ALT>2.0× the upper limit of normal, (b) prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy >6 months before study initiation, (c) ingestion of prescription, over the counter, or herbal medications affecting gastrointestinal transit or study interpretation within 6 months of study initiation for controls or within 2 days before study initiation for IBS patients, (d) pregnant females, (e) antibiotic usage within 3 months before study participation, (f) prebiotic or probiotic usage within the 2 weeks before study initiation, (g) tobacco users. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis and frozen. Frozen aliquots will be shipped to the Metabolite Profiling Facility at Purdue University and the Mayo Clinic Department of Laboratory Medicine and Pathology for SCFA and bile acid measurements, respectively. Analysis of fecal microbiota will be performed in the research laboratory of Dr David Nelson in collaboration with bioinformatics expertise affiliated with the Nelson lab. Colonic transit time will be measured with the previously validated method using radio-opaque markers. Generalized linear models will be used as the analysis framework for comparing study endpoints among groups. RESULTS/ANTICIPATED RESULTS: This study seeks to examine the innovative concept that specific microbial signatures are associated with increased fecal excretion of organic acids to provide unique insights on a potential mechanistic link between altered intraluminal organic acids and fecal microbiota. DISCUSSION/SIGNIFICANCE OF IMPACT: Results may lead to development of targets for novel therapies and diagnostic biomarkers for IBS, emphasizing the role of the fecal metabolome.https://www.cambridge.org/core/product/identifier/S2059866118000754/type/journal_article |
| spellingShingle | Andrea Shin David Nelson John Wo Michael Camilleri Toyia James-Stevenson Robert Siwiec Matthew Bohm Anita Gupta 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers Journal of Clinical and Translational Science |
| title | 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers |
| title_full | 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers |
| title_fullStr | 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers |
| title_full_unstemmed | 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers |
| title_short | 2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers |
| title_sort | 2103 fecal bile acids fecal short chain fatty acids and the intestinal microbiota in patients with irritable bowel syndrome ibs and control volunteers |
| url | https://www.cambridge.org/core/product/identifier/S2059866118000754/type/journal_article |
| work_keys_str_mv | AT andreashin 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT davidnelson 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT johnwo 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT michaelcamilleri 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT toyiajamesstevenson 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT robertsiwiec 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT matthewbohm 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers AT anitagupta 2103fecalbileacidsfecalshortchainfattyacidsandtheintestinalmicrobiotainpatientswithirritablebowelsyndromeibsandcontrolvolunteers |